ZNF236 and pancreatic adenocarcinoma: Lastly, AP002761.4 and ZNF236-DT appear to affect the immune microenvironment and tumor growth in acute myeloid leukemia (AML) (Zhao et al., 2024) and pancreatic adenocarcinoma (Huang et al., 2023), respectively.